^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecvayli (teclistamab-cqyv)

    i
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    Apply
    Immuno-PRISM (PRecision Intervention Smoldering Myeloma) (NCT05469893)
    Phase 2
    Irene Ghobrial, MD
    Recruiting
    Last update posted :
    08/01/2023
    Initiation :
    08/10/2022
    Primary completion :
    07/31/2030
    Completion :
    07/31/2030
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    lenalidomide • dexamethasone • Tecvayli (teclistamab-cqyv)
    Limited-duration Teclistamab (NCT05932680)
    Phase 2
    Abramson Cancer Center at Penn Medicine
    Recruiting
    Last update posted :
    07/27/2023
    Initiation :
    07/05/2023
    Primary completion :
    06/01/2025
    Completion :
    01/01/2027
    CD8 • CD4
    |
    Tecvayli (teclistamab-cqyv)
    Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) (NCT05161598)
    Phase N/A
    Janssen Research & Development, LLC
    No Longer Available
    Last update posted :
    08/16/2022
    XPO1
    |
    Tecvayli (teclistamab-cqyv)